The Kita-Kyushu Lung Cancer antigen-1 (KK-LC-1) is a cancer/testis antigen (CTA) that is expressed in multiple solid tumors while restricted to germ line cells in normal tissues. T-Cure estimates that KK-LC-1 is expressed in 80% gastric cancer, 75% triple negative breast cancer (TNBC), 45% non-small cell lung cancer (NSCLC) and 40% cervical cancer. 820TCR was isolated from a complete responder patient after Tumor Infiltrating Lymphocytes (TIL) therapy.

A Phase 1 clinical study is currently underway at the National Cancer Institute (NCI) and Rutgers University, investigating the potential of 820TCR based therapy (NCT05035407). This study aims to evaluate the effectiveness and safety of this therapy in patients. In parallel, the 821TCR program is in the pre-clinical development stage. This program focuses on targeting KK-LC-1 in a different HLA-class I haplotype, with the goal of expanding the pool of eligible patients for TCR-T therapies by including those with KK-LC-1-expressing tumors.

Using its iSORT platform, T-Cure identified 806TCR, an NY-ESO-1-specific TCR restricted to HLA-A2 haplotype. The 806TCR is in IND-enabling studies. NY-ESO-1 has been demonstrated clinically as a suitable target for TCR therapies for multiple solid tumors. T-Cure is currently exploring partnerships in developing “off-the-shelf” approaches to utilize this all natural but high affinity TCR in the clinic. T-Cure believes the 806TCR holds great promise as a component of such therapies.